First-Line Nivolumab + Ipilimumab in Patients Without Nephrectomy in the CheckMate 214 Trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
First-Line Nivolumab Plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
Eur Urol 2021 Nov 05;[EPub Ahead of Print], L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, C Porta, T Powles, F Donskov, S George, CK Kollmannsberger, H Gurney, MO Grimm, Y Tomita, D Castellano, BI Rini, TK Choueiri, D Leung, SS Saggi, CW Lee, MB McHenry, RJ MotzerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.